Quantcast

Latest Sanofi Stories

2014-02-11 08:30:49

- Fourth quarter 2013 EYLEA® (aflibercept) Injection global net sales were $586 million, consisting of $402 million in the U.S. and $184 million in rest of world(1) TARRYTOWN, N.Y., Feb. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the fourth quarter and full year 2013 and provided an update on development programs....

2014-02-06 08:27:40

PARIS, Feb. 6, 2014 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q4 2013 Change (reported) Change (CER) 2013 Change (reported) Change (CER) Net sales EUR8,457m -0.8% +6.5% EUR32,951m -5.7% -0.5% Business net income(1) EUR1,810m...

2014-02-05 08:29:22

Strategic Business Leader Brings Complementary Product Commercialization and Rare Disease Expertise SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), an innovative biotherapeutics enterprise, announced today that Frederic Chereau has joined aTyr as president and chief operating officer. Mr. Chereau has more than 20 years of experience in bringing new rare disease products to market and has held key leadership positions at Shire and Genzyme. Mr. Chereau's appointment will...

2014-02-05 08:29:18

-Regulus to Develop microRNA-21 for Alport Syndrome, a Life-Threatening Orphan Kidney Disease, and microRNA-21 in Oncology, to Human Proof-of-Concept- LA JOLLA, Calif., Feb. 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS) announced today that it has renewed its strategic alliance with Sanofi to discover, develop, and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Regulus will lead development of its fibrosis...

2014-02-04 12:28:20

First and only medicine in its class approved for over-the-counter use that provides 24 hour relief of the full range of nasal allergy symptoms including nasal congestion BRIDGEWATER, N.J., Feb. 4, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its U.S. consumer healthcare division Chattem announced today that Nasacort(®) Allergy 24HR Nasal Spray is now available over-the-counter (OTC) in the U.S. to relieve the full range of seasonal and year-round nasal allergy...

2014-01-28 08:29:50

PLANTATION, Fla., Jan. 28, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that it has hired Dr. Richard Scheyer as Vice President and Chief Medical Officer, Mr. Ira Weisberg as Vice President, Commercial Operations and Mr. David Crockford as Vice President, Regulatory Affairs. All three new executives will report to Dr. James New, the Company's President and Chief Executive Officer. Dr. Richard Scheyer Dr. Richard Scheyer has 30 years of...

2014-01-15 08:29:16

NEW DELHI, January 15, 2014 /PRNewswire/ -- - Cold and Cough remedies has conventionally remained the leading segment of the industry with a value share of 24.9% of the total sales as of 2012 - The vitamins and mineral supplements sales value have increased predominantly over the years from USD 873.9 million in 2006 to USD 1,091.9 million in 2012 - Slovakia has emerged as the fastest growing market for OTC drugs in the region...

2014-01-13 04:20:50

TARRYTOWN, N.Y., Jan. 13, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has amended and restated its investor agreement with Sanofi (EURONEXT: SAN and NYSE: SNY), which was originally entered into in December 2007. Under the terms of the amended and restated agreement, Sanofi retains its right to acquire up to 30% of Regeneron's outstanding common stock and Class A stock and gains the right to nominate a single independent director to...

2014-01-08 12:28:46

SARASOTA, Fla., Jan. 8, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Geoffrey F. Cox, Ph.D., to serve on its board of directors. Dr. Cox, currently an independent consultant to the Biotechnology and Life Sciences Industry and Principal of Beacon Street Advisors, brings to the company significant experience of the biotechnology industry, through a number of positions as a Senior Executive...

2014-01-08 08:28:31

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 8, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Express Scripts Holding Company (NASDAQ: ESRX), Sanofi SA (ADR) (NYSE: SNY), Agilent Technologies Inc. (NYSE: A) and Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH). Today's readers may access these reports free of charge - including full price targets,...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.